submissions

THE REGULATORY PROCESS
The Division of Clinical Laboratory Devices (DCLD) is currently composed of 50 scientists ranging from medical technologists to clinical pathologists who are collectively involved in the premarket review of in vitro diagnostic devices.' In general we process two types of submissions.
New versions of old devices are "cleared" (the specific term used is "cleared") as premarket notifications [1] .Because the regulation cited is the 5 10(k) regulation in the Code of Federal Regulations, these are referred to as 5 10(k) submissions.
Fundamentally new devices are "approved"
(the specific term used is "approved") as premarket applications (PMAs) [2] . In the semantic framework of Food and Drug Administration (FDA) language, a determination of whether a device is considered old or new is made on the basis of whether it was in the commercial marketplace or traceable to the commercial marketplace at the time of passage of the Medical Device Amendments of 1976. An in vitro diagnostic test is essentially a laboratory test.
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The largest volume of review activity for FDA involves 510(k) submissions.
DCLD currently handles -1000 51 0(k)s per year. The operative term in 510(k) review is "substantially equivalent." As the term implies, evaluation is directed at determining if the new device is equivalent to its identified predicate. Review of most 5 10(k) submissions is straightforward and based on an analysis of the fundamental operating principles of a test including accuracy, precision, analytical sensitivity, and analytical specificity.
Limitations in the review process are also quite straightforward.
5 10(k) review is entirely a paper review; FDA does not perform direct laboratory evaluation on any of these devices and the agency therefore has no hands-on experience with the vast majority of products under review. In addition, the agency is continually challenged by the need to determine appropriate minimum standards for the substantial equivalence decision. The FDA goal for 510(k) submissions is to process these with a total review time of 90 days. Reviews are generally conducted internally, although occasionally a product will be sent to outside experts employed as "special government employees" for outside grounding and input as a so-called "homework" assignment.
In very rare instances a formal public panel meeting may be held to deal with an unusual or problematic 510(k) submission. for use of a product will determine the type of review, the questions likely to be raised, and the data requirements that will be required in the course of review.
PMAS
DEVELOPMENT OF A SCIENTIFIC REVIEW MODEL
A central concern of the Office of Device Evaluation over the past several years has been development of a strong but pragmatic scientific model to frame our review. DCLD believes that while there is not one path to truth in terms of the development of information to support an in vitro diagnostic product, there are several basic tenets for good science. These include the need for:
1) Up-front study design. The bottom line for in vitro diagnostic devices is that DCLD currently reviews all commercially marketed laboratory devices with the clear goal to ensure product safety and effectiveness. We believe there is value added as a result of our review in at least three ways: (a) we provide for oversight and objective review of new laboratory tests, (b)we set and maintain minimum thresholds for product safety and effectiveness, and (c) we ensure that organized data and appropriate labeling are provided to the users in support of a device's intended use.
In a perfect world perhaps this review might not be necessary. In the highly competitive world of in vitro diagnostic devices, this degree of oversight is a protection to laboratories and the patients they serve in helping to ensure quality devices from (a) new companies unfamiliar with good science and regulatory requirements and (b)old companies that for various reasons exhibit quality drifts.
The outcome of FDA oversight is difficult to measure. The GAO report has not been replicated. The main mechanism FDA has for tracking product successes and failures in the general marketplace is through the proficiency testing available. Certainly there is no evidence in 1995 of parallels to the 75% failure rate reported by CDC in 1975, but, contrary to popular belief, problems are identified in the use of in vitro diagnostic devices, ranging from reported and unreported product recalls to medical device reports of both morbidity and mortality. Last year 2000 medical device malfunction reports for DCLD products were filed. Although most centered on two product lines, home glucose and pregnancy testing, many other problem products were identified. The medical literature has a small but interesting and growing number of reports of product failures. Last April a problem with positive 1gM rubeola tests was reported in the New England Journal of Medicine [4] . The authors took FDA to task for failing in its job. They were obviously unaware that for historic reasons unclear to us, 1gM rubeola tests are exempt, i.e., not subject to FDA review. FDA does its part in identifying and trying to head off product problems. For example, in October of 1995, FDA issued a product recall and consumer alert because of failures in test strips for home glucose monitors.
DOCUMENTING
RESULTS OF THE REVIEW PROCESS
Part of the FDA problem in documenting the good work that I believe FDA does is the fact that much of this work is invisible. It is estimated that only -2% of products submitted to FDA are found to be unsatisfactory and are either rejected by the agency or voluntarily withdrawn. Products that have been rejected or withdrawn are considered proprietary, and information about them is not available through the usual freedom-of-information reporting systems. The dazzling array of device design and performance failures that lead to rejection are, from the standpoint of the clinical laboratory and the public, simply hidden.
Also, the impact of FDA review is largely undocumented for cleared products.
Over 15% of 510(k) submissions processed raise sufficient concerns to be issued deficiency letters. This means two or more review cycles before clearance. There are three common types of deficiencies identified: inadequate performance data, incorrect or incomplete labeling, and fundamental design problems. FDA reviewers, through the questions and suggestions raised in their deficiency letters, attempt to improve and refine products in these three areas.
FDA has never performed an audit of the impact of this review because frankly we did not appreciate that appropriate methodology for such a study existed. We now realize that this is not the case. In July of 1994 the editors of the Annals of Internal Medicine published a fascinating article entitled "Manuscript Quality Before and After Peer Review and Editing at Annals of Internal Medicine [5] ."They reported significant improvement in 34 quality items as a result of the peer review process. Of particular interest to us at the FDA were the marked improvements and changes in the study limitations, generalizations, and conclusions reached. These represent areas of review that some would suggest we routinely obsess over.
As scientists engaged full time in this type of review activity, we believe that our review contribution is comparable with that reported in the above-mentioned article, albeit documentation of this process remains to be performed.
Whereas the public health benefits of FDA review of performance and labeling are difficult to assess, the up-front requirement for minimum standards in instrumentation and laboratory reagents is consistent with the modern pursuit of a controlled laboratory environment to assist in total quality management of laboratories.
THE FDA BACKLOG-PROBLEMS IN THE APPLICATION OF GOOD SCIENCE TO FDA REVIEWS
The application of a heightened scientific review model coupled with the increasing complexity of products developed and submitted to FDA by industry has been intellectually exciting but administratively problematic.
We have over the past several years experienced an imbalance between work force and work load. The result has been a backlog in products.
We take this backlog seriously. FDA recognizes that it has a twofold responsibility:
(a) to keep poor products out of the commercial marketplace, and (b) to assist manufacturers in bringing innovative and good products to the marketplace in a timely fashion.
We have been struggling over the past year to bring the total review times within the FDA goal of 90 days for routine 5 10(k) submissions, with some success. The good news is that our product backlog-defined by FDA as products under active FDA review for >90 days (either on initial evaluation or during a reevaluation in response to FDA questions raised)-has dropped from 90 products as recently as 1 year ago to zero. The bad news is that during this period, total review time has remained fairly constant at -135 days. Part of this lingering delay represents the residual challenge of dealing with a large work load with a limited work force. It is worth noting that in product review, quality submissions do pay off. In a small administrative pilot study conducted by DCLD earlier this year, we isolated 10 submissions that closely followed well-established guidance documents.
Average review time for these was only 70 days.
Although our review times have markedly improved, given our current resources and the increasing number and complexity of premarket submissions, it is unlikely that a total review time of 90 days can be achieved. As a result we are looking for tools to help bring balance to our program.
A number of office-wide and DCLD-specific programs are being explored, some of which cut across review of all medical devices and others which are specific to in vitro diagnostic products. FDA will be seeking outside input from both healthcare professionals and manufacturers as it seeks to improve and refocus the way it conducts premarket review. Although we expect that the results of these efforts will be changes in the traditional manner in which we do handle submissions, it is our clear goal to maintain sound science as a basis for future regulatory changes.
